A phase I study of MK-0646, a humanized monoclonal antibody against the insulin-like growth factor receptor type 1 (IGF1R) in advanced solid tumor patients in a q2 wk schedule

被引：36

作者：

Hidalgo, M.

Gomez, M. Tirado

Lewis, N.

Vuky, J. L.

Taylor, G.

Hayburn, J. L.

Hsu, K.

Kosh, M.

Picozzi, V. J.

机构：

[1] Johns Hopkins Univ, Baltimore, MD USA

[2] Univ Puerto Rico, Ctr Canc, Puerto Rico, PR USA

[3] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA

[4] Virginia Mason Med Ctr Mailstop, Seattle, WA USA

[5] Merck & Co Inc, N Wales, PA USA

来源：

关键词：

D O I：

10.1200/jco.2008.26.15_suppl.3520

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3520

引用

页数：1